LY 2189102

Drug Profile

LY 2189102

Alternative Names: IL-1β antibody - Eli Lilly; LY2189102

Latest Information Update: 29 Apr 2013

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antibodies; Antihyperglycaemics; Antirheumatics
  • Mechanism of Action Immunosuppressants; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 17 Apr 2013 Discontinued - Phase-I for Cardiovascular disorders in USA (Parenteral)
  • 16 Sep 2011 Final efficacy and adverse events data from a phase II trial in Type-2 diabetes mellitus presented at the 47th Annual meeting of the European Association for the Study of Diabetes (EASD-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top